IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
KDMN News
Archived Headlines
- Kadmon prices IPO at $12, the low end of the range 07/26/16
- Kadmon decreases proposed IPO deal size 07/26/16
- US IPO Week Ahead: High-growth tech firm Talend leads week with 4 IPOs 07/22/16
- US IPO Weekly Recap: LINE and AdvancePierre trade up on market debut 07/15/16
- Former ImClone CEO's biotech Kadmon sets terms for $100 million IPO 07/14/16
See more
US IPO Weekly Recap: June kicks off to a slow start with 2 IPO pricings but only one trading
Two IPOs priced in the first week of June; only one has started trading Four companies added to the calendar (including two SPACs) ...read more
US IPO Week Ahead: 2 IPOs in the first week of June; more launches expected
It's a slow start to the typically-active month of June, but that should change soon. Two companies are targeting a combined $158 million in the week ahead. Deals include Taiwan-based live streaming company M17 Entertainment and gene therapy biotech MeiraGTx. ...read more
US IPO Weekly Recap: 4 IPOs price, Talend on top, Kadmon a flop
Four IPOs raised $315 million during the last week of the month, bringing July’s deal count to ten and signaling that IPO activity has not yet taken a vacation. Further evidence of a gradual tech IPO recovery materialized with cloud-based software provider Talend rocketing 42% higher on its debut, after pricing 13% above the midpoint. On the other hand, cash-burning drug...read more
Kadmon plummets 19% on offering; 10 of 12 biotech IPOs since April 1 are below issue
Kadmon (KDMN) raised $75 million (53% insider) on its IPO and proceeded to drop 19% on Wednesday, the year's second-worst debut. Kadmon is only the latest in a string of biotech IPOs that have disappointed. Of the 12 biotechs that have IPO'd since the second quarter began, 10 currently trade below issue (82%) and the group's average return is -15%, mirroring the...read more